Melatonin

With peptides

Melatonin pairs with the sleep and cognitive peptide cluster via distinct mechanisms. DSIP (delta sleep-inducing peptide) is reported to act on slow-wave sleep architecture — a different layer than melatonin's circadian signaling. Selank (a tuftsin analog) is reported to provide anxiolytic effects via GABA modulation. The combination is described as covering three sleep mechanism layers: circadian signaling (melatonin), slow-wave architecture (DSIP), and arousal/anxiety modulation (Selank). Epitalon is a pineal-axis peptide discussed as potentially supporting endogenous melatonin production, with some mechanistic overlap. No negative interaction across the sleep peptide cluster is documented in the sources reviewed for this page.

With supplements

1. Apigenin — a GABA-A positive allosteric modulator, reported as a distinct receptor system from melatonin's circadian mechanism.
2. Glycine — trials dosed around 3 g pre-bed for body-temperature regulation at sleep onset, a different mechanism from melatonin.
3. Magnesium glycinate — GABAergic and neuromuscular relaxation, a common co-occupant in sleep-stack products.
4. Tart cherry — a natural melatonin, tryptophan, and anthocyanin botanical matrix, providing an endogenous melatonin contribution alongside a supplemental dose.
5. L-theanine — reported for alpha-wave relaxation and pre-sleep mental wind-down, a distinct mechanism from melatonin's circadian signaling.
6. GABA — direct GABAergic supplementation; blood-brain barrier penetration for oral GABA is debated in the literature.

With lifestyle factors

1. Consistent sleep schedule. Melatonin's circadian-signaling mechanism is reported to work best alongside consistent sleep timing; variable bedtimes are reported to undermine the effect.
2. Evening light exposure. Dim/red light in the hours before bed is reported to support endogenous melatonin production, while bright/blue light suppresses it.
3. Bedroom temperature. A cooler bedroom (~65–68°F / 18–20°C) is reported to support the body-temperature drop melatonin facilitates.
4. Pre-flight jet lag protocol. Trials cited above adjusted melatonin timing 2–3 days before travel for eastward shifts, dosed at destination bedtime rather than flight bedtime.
5. Intermittent use for chronic protocols. Given the preliminary AHA 2025 long-term signal, intermittent/situational use over continuous multi-year nightly use is the more conservative approach described above pending more rigorous evidence.
6. CBT-I for chronic insomnia. Cognitive-behavioral therapy for insomnia is described in clinical guidance as first-line for chronic insomnia disorder, with melatonin positioned as an adjunct rather than a substitute for behavioral therapy.

Common (mostly transient)

1. Morning grogginess — reported more often with higher doses (5+ mg) and extended-release formulations; labels commonly note lower-dose or immediate-release options reduce this.
2. Vivid dreams or nightmares — reported relatively commonly, particularly at higher doses.
3. Headache — reported occasionally, generally mild.
4. Daytime drowsiness — reported as uncommon with trial-matched timing; more likely with extended-release or evening dosing.

Less common (watch-list)

1. Long-term cardiovascular signal (AHA 2025 preliminary). The preliminary AHA Scientific Sessions 2025 observational analysis (130,828 adults, 5-year TriNetX record review) reports melatonin users at nearly 3.5× the rate of heart failure hospitalization (19.0% vs. 6.6%), nearly 2× the all-cause mortality (7.8% vs. 4.3%), and roughly 90% higher incident heart failure diagnosis (4.6% vs. 2.7%) versus matched non-users at 1+ years of use. The study's authors state this is observational, not peer-reviewed, and cannot prove causation.
2. Hormonal pathway questions in children — melatonin is a hormone, and pediatric guidelines note open questions about whether chronic supplementation during development affects puberty timing or related axes, which is why pediatric use is generally restricted to specialist-supervised clinical indications.
3. Label-vs-actual content variance — Erland & Saxena 2017's independent testing documented significant melatonin content variance from labeled dose in sampled commercial products.
4. Mood changes — rare reports of depression or irritability worsening exist in the literature, described as mostly anecdotal.

Drug and supplement interactions

1. Anticoagulants (warfarin, apixaban, rivaroxaban). A mild additive anticoagulant effect is reported as possible; INR monitoring is standard guidance for warfarin users on melatonin.
2. Immunosuppressants (cyclosporine, tacrolimus). Melatonin is reported to potentially affect immune-modulator drug metabolism; coordination with the prescribing clinician is standard guidance.
3. Diabetes medications. Melatonin is reported to modestly affect glucose metabolism; glucose monitoring is standard guidance when combined with insulin or oral diabetes medications.
4. Hormonal contraceptives. Estrogen is reported to affect melatonin metabolism, which can raise circulating melatonin levels and amplify its effects.
5. Sedatives (benzodiazepines, Z-drugs). Additive sedation is reported; total sedation load is the standard consideration.
6. Fluvoxamine (SSRI) — reported to significantly increase melatonin levels via CYP1A2 inhibition; a lower melatonin dose is the standard guidance for users on fluvoxamine.
7. Pregnancy and breastfeeding — data are limited; melatonin is reported to cross the placenta and enter breast milk, and clinician guidance is standard practice in this context.

What dose of melatonin is used in trials and on labels?

Trial and label doses commonly range 0.5–3 mg, taken 30–60 minutes before bed — the range used across the trials cited below (Ferracioli-Oda et al. 2013's meta-analysis of 19 RCTs, Herxheimer & Petrie 2002's jet lag trials). Most retail products are dosed at 3, 5, or 10 mg, well above the body's natural peak nighttime production (roughly 0.3 mg equivalent, per the trial base cited below) and above the range most represented in the positive trials. Higher doses are reported to bring more next-day grogginess and vivid dreams without a clearly established additional sleep benefit, though no meta-analysis identified for this page maps a specific dose-response curve or plateau point for melatonin's sleep effect.

What does the evidence say about long-term nightly use?

Short-term use (up to a few months) at low doses is reported as generally well-tolerated across the trial base cited below. Long-term nightly use — beyond about a year — is less studied by RCT, and a preliminary observational analysis presented at the American Heart Association's Scientific Sessions 2025 raises a specific concern: in a TriNetX electronic-health-record review of 130,828 adults with insomnia (65,414 melatonin users, 65,414 matched controls) followed over 5 years, melatonin users were reported as nearly 3.5 times more likely to be hospitalized for heart failure (19.0% vs. 6.6%) and nearly twice as likely to die from any cause (7.8% vs. 4.3%); incident heart failure diagnosis was about 90% higher (4.6% vs. 2.7%). The study's own authors state this is a research abstract, not peer-reviewed, and cannot establish cause and effect — the finding is preliminary until published as a full peer-reviewed manuscript.

Is morning grogginess reported at low or high doses?

The trial base and product labeling describe morning grogginess as more associated with higher doses (5–10 mg) and extended-release formulations than with low doses (0.5–3 mg). Labels commonly note that lowering the dose or switching from extended-release to immediate-release reduces this effect. Roughly half the population are slow CYP1A2 metabolizers — the same enzyme that metabolizes caffeine — and this subgroup is reported to experience longer-lasting effects from a given dose.

Is melatonin acting as a sedative or a circadian signal?

The mechanism described in the literature is circadian signaling rather than sedation. Melatonin works through MT1 and MT2 receptors to signal darkness/nighttime to the suprachiasmatic nucleus — a different mechanism from benzodiazepines or Z-drugs. This is reported as the reason melatonin is most useful for circadian rhythm disruption (jet lag, shift work, delayed sleep phase disorder) and shows a smaller effect for general insomnia. Effect sizes in general-insomnia trials are modest: Ferracioli-Oda et al. 2013's meta-analysis reports roughly 7 minutes faster sleep onset and roughly 8 minutes additional total sleep time versus placebo.

Does melatonin stack with DSIP or other sleep peptides?

The mechanisms are reported as distinct and non-overlapping. DSIP (delta sleep-inducing peptide) is reported to act on slow-wave sleep architecture — a different layer than melatonin's circadian signaling. Selank (a tuftsin analog) is reported to provide anxiolytic effects via GABA modulation, relevant when sleep is disrupted by anxious arousal rather than circadian timing. The combination covers three distinct mechanism layers — circadian signaling (melatonin), slow-wave architecture (DSIP), and arousal/anxiety modulation (Selank) — plus apigenin (a GABA-A modulator) as a botanical fourth layer. No negative interaction between these is documented in the sources reviewed for this page.

What do pediatric guidelines say about melatonin in children?

Pediatric guidelines generally reserve melatonin for children with neurodevelopmental sleep disturbances (autism spectrum disorder, ADHD-related sleep issues) under pediatrician supervision, rather than routine self-administration in healthy children. Melatonin is a hormone, and open questions remain about whether chronic supplementation during development affects puberty timing, growth hormone axis, or other hormonal pathways. Retail melatonin gummies marketed for children have drawn scrutiny for being poorly aligned with this narrower evidence base.

Why do EU/UK melatonin doses differ from US products?

The regulatory framing differs. In the US, melatonin is sold as a dietary supplement, not FDA-regulated as a drug, and is available over-the-counter at any labeled dose. In the EU and UK, melatonin is regulated as a prescription medication (marketed under brand names such as Circadin), typically at 2 mg extended-release for primary insomnia in adults over 55. Practical effect: US products span a wider dose range with less regulatory quality control on label accuracy; EU/UK products carry tighter pharmaceutical-grade dosing but require a prescription.

How long does it take to work, and how long does the effect last?

Peak plasma concentration is reported at 30–60 minutes after an oral dose. The half-life of immediate-release melatonin is reported at 30–50 minutes — short enough that levels are largely cleared by morning. Extended-release formulations (Circadin and similar) extend the effect over 6–8 hours but are reported as more likely to cause morning grogginess. Trial protocols for sleep onset generally dosed 30–60 minutes before target bedtime; circadian phase-shifting protocols (jet lag, shift work) use different timing depending on shift direction. Dosing melatonin in the middle of the night, rather than before bed, is reported to work against its own circadian signal.